Paliperidone : Therapeutic uses, Dosage & Side Effects
Paliperidone (9-hydroxyrisperidone , metabolite of risperidone) is a second-generation atypical antipsychotic drug, used in treating schizophrenia or schizoaffective disorder. It may also be used for other conditions as determined by your doctor.
Dose : mg
Route : Oral
Plasma Half-life : 23 hours (oral)
Duration of action : ?
Bioavailability : 28% (oral)
Chemical formula : C23H27FN4O3
IUPAC name : (RS)-3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one
Trade name : Invega, Invega Sustenna, Xeplion, Invega Trinza
Therapeutic uses :
Paliperidone has following usage :
- Primarily indicated as anti-psychotic drug for treating psychoses particularly Schizophrenia (generally first-line therapy).
- Approved for the treatment of schizoaffective disorder.
- May be indicated for the treatment of bipolar disorder, mania.
- May be used for Organic brain syndromes on a short-term basis.
- Rare indications includes Alcoholic hallucinosis, Huntington’s disease and Gilles de Ia Tourette’s syndrome.
Side effects : Adverse effects of the Paliperidone can occur in practically all patients and are significant in about 80% ; It may produce following side effects:
- CNS ailments like Sedation, drowsiness, lethargy, mental confusion, increased appetite, weight gain, aggravation of seizures
- CVS effects including Postural (orthostatic) hypotension, palpitation, inhibition of ejaculation
- Anticholinergic effects such as Dry mouth, blurring of vision, constipation, urinary incontinence
- Rarely Hyperprolactinemia – amenorrhoea, infertility, galactorrhoea and gynaecomastia
- Rarely Extrapyramidal disturbances (extrapyramidal symptoms EPS) such as Parkinsonism, Acute muscular dystonias, Akathisia, Malignant neuroleptic syndrome, Tardive dyskinesia
Warnings :
- Increased Mortality in Elderly Patients with Dementia-Related Psychosis
Contraindications :
- It should be used cautiously in patients with seizure disorders (since it may lower the seizure threshold)or those with an increased risk for seizures, such as withdrawal from alcohol.
- Paliperidone extended-release tablets are contraindicated in patients with a known hypersensitivity to either Paliperidone or risperidone, or to any of the excipients in the Paliperidone extended-release tablets formulation. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with Paliperidone.
For detailed query or in case of uncertainty, Always consult your doctor or pharmacist.
